The latest technologies in connected medical devices, digital health and mobile apps for the pharmaceutical and medical device industries
17-18 Oct 2019
GBP 1,499 1,299 *
EUR 2,099 1,819 *
USD 2,338 2,026 *
* When you book before 23 Aug
Our media partner
We are in the midst of an innovative period in medical technology and digital health and this brings huge opportunities for the pharmaceutical and medical device industries to revolutionise drug delivery. The market size in this area is expected to grow rapidly and a key goal for major players is to harness these technological advances to improve patient safety, experience, convenience and compliance, whilst meeting the regulatory requirements and complying with the legal demands surrounding data security.
Key experts from a variety of disciplines in the areas of connected drug delivery and digital health will explore ways to exploit the technology available to enhance drug delivery and will discuss the challenges, opportunities and how to:
This programme will provide valuable insights into the use of connected devices for drug delivery and will enable you to:
Chair’s welcome and introduction
Dr Gregory Berman
Opening address: How pharmaceutical companies and drug delivery device developers integrate connectivity into innovative health solutions
Key aspects of how better security and good governance over personal data will enable better global healthcare
Understanding legal risk from data breaches in the digital health ecosyste
Panel discussion: Is our health data safe?
Led by Dr Gregory Berman with Neil Williams, Caroline Rivett and Paul Glass
Multi-sensor remote data collection – critical success factors
Marie McCarthy (tbc)
Next generation drug delivery: needle-free and connectivity
Digital education in endoscopy
Smart packaging – improving patient outcomes through targeted application of smart technologies
Review of day one
Dr Gregory Berman
Why medical technology needs to get serious about investing in digital health
Regulatory requirements for connected medical devices
Digital health partnering agreements
Colin McCall and Jo Joyce
Innovative technology approach in wearable health – example of a successful cooperation between research institutes and industrial players
Connecting the dots between patients and medical devices
Successful implementation of connected drug delivery devices: lessons from diabetes
Eye tracking evolution in medical device development
Chair’s concluding remarks
Gregory Berman is an Independent Consultant and Director of Cantab Innovations Ltd. Previously he was Head of the Medical Group at Kinneir Dufort, an award-winning research, innovation, design and product development company, with over 30 years’ experience helping companies discover, create, develop and realise tangible new products, brands and experiences. He helps clients in the life-science, medical and healthcare sectors to develop products in complex situations, optimise life-science R&D and exploit technology strategically.
He led the design and development of SmartJect™; an autoinjector which automatically retracts the needle and was launched by J&J in 2010 with an important next-generation drug.
Worked with Chrono Therapeutics, helping to develop their SmartStop™ based device, the world’s first programmable, wearable transdermal smoking cessation therapy.
Participated in a detailed design review of an autoinjector being developed by a leading pharmaceutical company for a new drug.
Undertook the Voice of Customer study for a leading biopharmaceutical company, as the starting point for developing high volume parenteral delivery devices for lifesaving immunotherapies.
Undertook a technology survey for a company interested in needle-free, transdermal, micro-needle, electroporation and iontophoresis drug delivery devices.
Phil Seeney is a Managing Consultant in the Technology and Innovation Practice within the PA Consulting Group. He holds a BSc (First Class Hons) in Mechanical Engineering from Aston University (1975) a DIC from Imperial College London and an M.Des from the Royal College of Art, London. Phil developed strong engineering skills in industry transitioning to product design and medical device development after studying at Imperial College and the RCA. He has over 40 years of product development experience covering fast moving consumer goods, consumer durable and healthcare sectors. For the last 25+ years, Phil has specialized in drug delivery and the development of medical devices. His experience extends beyond the development of products and he has conducted numerous technology identification and due diligence projects for blue chip pharmaceutical clients. Phil is no stranger to tackling the wider business issues and has assisted various clients in developing low cost manufacturing strategies and realizable cost reduction programs. Phil has a keen interest in the application of technology to improve patient benefits and outcomes and has written articles on the use of technology in connected drug delivery devices and in the future of inhalation.
Chris Waterhouse is an experienced Project Manager specialising in the integration of manufacturing and supply chain operations with packaging technology.
Highly motivated and an innovative thinker with a track record of delivery in demanding situations he has a wide ranging expertise in Supply Chain operations and processes, originally centred on the manufacturing and packaging arenas.
In recent years he has worked at senior level in Regulated Industries; Agro-Chemical, Pharmaceutical and Healthcare and as such has been regularly involved with the subject area.
Recent programs of work have included:
a. Packaging redesign to facilitate improved protection
b. JIT Packaging Manufacture, not manufacturing!
c. Development of digital approaches for anti-counterfeit purposes
Chris is a Fellow of the Institute of Packaging.
Dr. Patrick Anquetil is Portal Instrument’s Chief Executive Officer. He brings more than 18 years of experience in nanotechnology, including extensive knowledge in the areas of cleantech, material science, and instrumentation.
From 2009 to 2012, he was co-founder and director of strategic and process planning for SynapDx Corporation, where he had responsibility for development of the company’s business and operational plans as well as securing $9 million in Series A funding. He began his career as a science and nanotechnology equity research analyst at Susquehanna International Group, authoring and marketing nanotechnology industry and equity research reports to hedge funds and portfolio managers. He holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard University, and a master’s degree from the ETH in Zurich and the University of Tokyo. His work has appeared in numerous peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC among others.
Colin is a senior associate in Taylor Wessing’s Intellectual Property department. His practice focuses on commercial aspects of the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors, and he advises on both non-contentious and contentious matters. He has been described in Legal Directory Chambers and Partners as “very sharp and intelligent” and a “very good IP all-rounder” and as a key individual for having impressed clients with his “very practical” approach, and with his ability “to give you business like solutions”. He also has a first class degree in Cell Biology from Durham University, a Diploma in Intellectual Property Law and Practice from Bristol University and an MSc in Energy, Environmental Technology and Economics at London City University. His specialities include life sciences, healthcare, medtech and cleantech.
Francis White, Director of Medical and Surgical Business for Olympus, the UK’s largest MedTech employer, leads with passion and enthusiasm for the patient; remembering that all the cutting edge medical technology and continued drive for high performances only make sense when chosen by our customers.Previously holding the International VP leadership position at AliveCor (a Silicon Valley AI company) and serving as an NHS Innovation Fellow; with a wealth of sector knowledge, having held a similar a senior position at Medtronic and others in the past 29 years. Always striving to continue to learn, have fun and help others to grow beyond limits; lucky to be a leader in the Medical Device sector where the possibilities for improving human health and well-being are only just beginning to be discovered…
Marie McCarthy is a Director of Product Innovation at ICON, and as part of a multidisciplinary innovation team, has specific responsibility for developing solutions in the direct to patient paradigm, including the operationalization of wearable devices. She has coordinated projects to collect data generated from wearable devices into a range of systems (e.g. EDC) and analytics platforms (e.g. Intel and ICONIK)
Marie acts in an advisory capacity for a number of sponsors on the relevant clinical endpoints and considerations to be deployed when embarking on the incorporation of wearable technology into clinical trials. As part of the ICON CNS innovation group she provides insight into outcomes addressed by wearable technology.
Prior to ICON, Marie worked at Philips Respironics, with responsibility for strategic European marketing decisions including the development and implementation of the international sales & marketing strategy for Actigraphy in both clinical and pharmaceutical market segments. She delivered the Actigraphy component of a number of educational programs including the Manchester Sleep Medicine Course, the Edinburgh Sleep Medicine Course, and workshops at the British Sleep Society (BSS) and European Society of Sleep Technicians (ESST). Marie was responsible for the support and training of researchers, clinicians and trial sites in the appropriate use of Actigraphy, and has a network of connections with leading clinicians and researchers throughout Europe.
Arnaud is currently business development associate at BIOCORP, in charge of finding partnerships and license opportunities for BIOCORP’s range of connected devices. Previously, he worked for a healthcare consulting firm with a strong focus on connected health strategies for pharma and insurance companies. Other past experiences in the pharmaceutical industry (Sanofi) and the insurance industry (AXA). Graduated from HEC Paris, a major European business school. For 20 years, BIOCORP has been designing, developing and manufacturing medical devices for the pharmaceutical industry, enhancing drug reconstitution, safety, packaging and delivery.
Neil is the Head of Connected Health and Director of Front-End Innovation for Medicom Innovation Partner, a Phillips-Medisize Company, based in Cambridge UK. Neil consults for BioPharma clients, innovating and executing strategies to enhance stakeholder engagement through connected devices and service design. He has over 22 years’ commercial experience covering medical devices, telemetry, digital imaging, clinical decision support, secure mobile working, patient engagement and health analytics for businesses including Philips Healthcare, Microsoft, Elsevier Health Sciences, Hospira, Map of Medicine and ZOLL. Prior to Neil’s commercial career he trained at Leicester University Hospitals in Operating Department Practice and was Faculty for numerous Advanced Life Support programs having qualified in the UK and United States.
Caroline Rivett is Head of Cyber Security, Healtcare Practice, KPMG, UK. Caroline leads KPMG’s UK cybersecurity team focusing on thier life sciences clients. She has over twenty years experience of managing and reviewing technology and risk. Over the last five years she has specialised in the protection of sensitive information in health and life sciences.
Caroline is the KPMG Account lead for cybersecurity and privacy services for a number of KPMG’s global pharmaceutical and research clients. Projects have included privacy strategy and contract remediation, production systems security and specialist security testing.
She recently hosted a conference on ‘Information Protection in Digital Health’ with attendees from pharmaceuticals, research, the NHS, construction, and academia. She is a Council member for the Royal Society of Medicine’s Telehealth & eHealth Council, a member of the Global Alliance for Genomic and Health Data Protection, and speaks at conferences on cybersecurity in pharmaceuticals, connected medical devices and digital health.
Prior to joining KPMG, Caroline co-founded a company which digitised and extracted data from medical health records which was subsequently sold to a US corporation. She developed the UK business focusing on life insurance companies and worked with them on security and protecting their customers’ sensitive personal data.
Caroline has led a number of change programmes. She previously set up a global shared services centre for a Big Four consulting company performing big data analysis for global clients. Whilst at Aviva she led a finance programme which analysed and costed technology services.
Mette Luxhoj, Senior Manager Regulatory Affairs, responsible for IT & Software Solutions, Transcutaneous Monitoring Systems, Innovation & New Technologies.
Supporting medical devices and IVD development and maintenance projects.
Main areas: compliance with medical device regulations and standards – software, cybersecurity and data privacy by design – innovation and new technologies.
Co-Chair MedTech Europe Software Working Group
Member of EU working groups: New and Emerging Technologies, Cybersecurity & Software
Former Danish representative at the International Medical Devices Regulators Forum (IMDRF)
Former Coordinator of Nordic Software Working Group at the Danish Medicines Agency.
Experienced project manager and consultant within healthcare innovation projects.
Paul Glass, is a Partner in the Disputes and Investigations group at Taylor Wessing LLP. He advises UK-based and international clients in the following areas:
Data security breaches and investigations, cybercrime and related litigation.
Technology and IT disputes.
Financial disputes, including complex financial products, CDOs, swaps and ISDA-related disputes.
Regulatory investigations, including ICO, FCA and FRC.
Sanctions, including compliance and investigation of potential breaches of sanctions.
Jo Joyce, Senior Associate, Data Protection Group, Taylor Wessing. Jo has been advising clients on contentious and non-contentious IP and data rights matters for over 9 years.
She works with clients to develop intellectual property and data protection strategies and policies and has spent several years focusing on GDPR preparation for international clients in particular. She spends a lot of her time delivering popular training courses pitched at all levels.
Her extensive work on cyber-security breaches and data and confidential information focused litigation means that she is well placed to help clients minimise risk and mitigate the liability that may arise from a breach-event, particularly in light of the new, heavier, liabilities that will be imposed under the GDPR.
John Jeans, is a Non-Executive Director and Mentor who chairs the Digital Health and Care Institute and serves on the Boards of EM Imaging and Renishaw plc. His previous positions include Chairmanships of Imanova Ltd and the UK BioCentre as well as Directorships of Alliance Medical, Prometic Life Sciences Inc, Prometic Pharma SMT Ltd and Myconostica.
He is a Fellow of the Royal College of Art and Cardiff University where he was previously the Chairman of Council and a Director of the University Employers Association. From 2009 John was Deputy Chief Executive of the Medical Research Council, a member of its Audit and Risk Committee and Chaired the Trustee Board of MRC Technology (LifeArc) until 2014.
An advisor to public and third sector organizations, he was appointed by the Prime Minister from 2014 to 2018 as the Life Science Champion for medical technology. John leads Innovate UK’s Health KTN Board, and has contributed to advisory panels for the MRC, EPSRC, NIHR, NCUB, NPL, HDRUK and the Wellcome Trust. He has served on several Government bodies including a Ministerial Committee on Medical Technologies, was an inaugural member of the Science Advisory Council for Wales and a founder Trustee of the Francis Crick Institute.
He is Chair of the Strategic Advisory Panel for the Singapore Government’s Diagnostics Hub, a member of its Advanced Manufacturing and Engineering Advisory Panel and its Health and Biomedical Sciences Advisory Council.
In an industrial career spanning 35 years he held senior international leadership positions in global companies including Smith & Nephew, Bristol Myers Squibb, Johnson & Johnson and Amersham plc. John headed the commercial function of GE’s Life Science business and was the Chairman of its UK Healthcare Company. His domain experience ranges from medical devices and therapeutic pharmaceuticals to in-vivo and in-vitro diagnostics; encompassing research, product development, manufacturing and commercialization.
John is engaged with international, national and local charities including the Africa Research Excellence Fund and is Co-Chair of the Clare Foundation.
He was awarded the CBE for services to Life Sciences, Healthcare and Science in 2012.
Thilo Schmierer, Business Development Manager Medical Solutions, Germany.
Thilo was awarded a Doctor degree in Chemistry at the University of Tübingen. After holding positions in R&D, Regulatory Affairs, Sales and Account Management in the Healthcare industry, he joined Datwyler Sealing Solutions in 2015, where he is responsibe for new business development in in the Medical Solutions segment.